Become a member today. It's free.
We will not release or resell your information to third-parties without your permission.
Resverlogix has a long way to climb back, but they're taking the first steps.
Another day, another bullboard war. But not much else.
Another day, another surprising block of Stockhouse user data.
Newcomers make the list on Stockhouse Research's roundup of what's hot on Stockhouse.com today.
Dear Fox: I think yours is an excellent post - bringing up a number of important points. The following passage mirrors something I...
The anguish of angiography Let us still have in mind, that a change of the coronary diameter is nothing but a surrogate outcome. It...
Yes it frustrating to say the least.
Agreed! (But still find it depressing down, down down in a drip,drip, drip fashion. Makes that $1.00 per share with the $4 milestone...